MaaT Pharma, SA
About MaaT Pharma, SA
MaaT Pharma (Microbiota as a Therapy) is a French biotech start-up, created at the end of 2014, to treat serious diseases linked to imbalances in the intestinal microbiome. It has developed the first treatment solution based on autologous microbiotherapy. MaaT Pharma envisages a first therapeutic application for patients suffering from leukaemia and bone & joint infections, whose major treatment contributes to dysbiosis. Funded jointly by a team which brings together world-class medical-scientific and entrepreneurial skills, MaaT Pharma has the ambition of becoming a leader in microbiome protection and the treatment of dysbiosis.YEAR FOUNDED:
2014
LEADERSHIP:
Co-Founder and CEO: Herve´ Affagard
Co-Founder and Non Executive President of the Board: Dr Pierre Belichard
Co-Founder: Mr. Joël Doré
Co-Founder: Mr. Pierre Rimbaud
CAREER:
Please click here for Auspherix's job opportunities.
PIPELINE:
Please click here for MaaT Pharma's pipeline.
58 articles with MaaT Pharma, SA
-
MaaT Pharma to Host First Virtual R&D Day on June 7th, 2022
5/24/2022
MaaT Pharmam announced that it will host its first R&D Day for analysts and investors to be held virtually on Tuesday, June 7th, 2022 from 4:00 pm CEST to 6:00 pm CEST.
-
MaaT Pharma Reports Cash and Revenues for First Quarter 2022
5/5/2022
Regulatory News: MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer reported its cash position as of March 31, 2022, and its revenues for the first quarter of 2022.
-
INRAE and MaaT Pharma Build on the Success of their Long-Standing Partnership with the Entry of Drug-Candidate MaaT013 into Phase 3 Clinical Trial
4/21/2022
MaaT Pharma announced on March 28th, 2022, the inclusion of the first patient in a pivotal Phase 3 clinical trial, potentially the last step of clinical development before marketing authorization, evaluating MaaT013 for the treatment of acute gastrointestinal Graft-versus-Host Disease, a serious complication following stem cell transplantation.
-
MaaT Pharma Publishes its 2021 Annual Results and Provides a Business Overview
4/14/2022
MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer reported full-year 2021 revenues and provided a business overview for 2022.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
MaaT Pharma Announces First Patient Dosed in Phase 3 ‘ARES’ Trial Evaluating MaaT013 in Patients with Acute Graft-vs-Host-Disease
3/28/2022
MaaT Pharma announced that the first patient has been dosed in its pivotal Phase 3 trial investigating MaaT013 in patients with acute Graft-versus-Host-Disease with gastrointestinal involvement who are refractory to both steroids, the standard of care first-line treatment, and to ruxolitinib1 used as a second-line treatment.
-
MaaT Pharma Announces the Implementation of a Liquidity Contract with Kepler Cheuvreux
3/21/2022
MaaT Pharma announced the implementation of a liquidity agreement with Kepler Cheuvreux to enhance the liquidity of the MaaT Pharma shares admitted to trading on Euronext Paris.
-
MaaT Pharma Reports Cash and Revenues for Full-Year 2021
2/28/2022
MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer reported its cash position as of December 31, 2021, and its full-year 2021 revenues.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study
1/24/2022
MaaT Pharma announced positive interim engraftment data from the first four cohorts of the CIMON trial with MaaT033, the Company’s high-richness, high-diversity, Microbiome Ecosystem Therapy for oral administration.
-
MaaT Pharma decided today to end the Phase Ib CIMON study for MaaT03, the company's second drug candidate and first oral formulation in Phase 1b clinical trial, following positive interim engraftment data of the drug.
-
MaaT Pharma Provides Business Objectives and Expected Milestones for 2022
1/17/2022
Important clinical milestones are expected in 2022 in the Company’s hemato-oncology and immuno-oncology programs.
-
MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas
1/13/2022
MaaT Pharma, a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, announces the initiation of coverage of its stock by KBC Securities, Kempen and Portzamparc / Groupe BNP Paribas.
-
MaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
1/3/2022
MaaT Pharma announced that its CEO and co-founder, Hervé Affagard will present the company at the upcoming H.C. Wainwright Bioconnect Virtual Conference held January 10-13, 2022.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting
12/11/2021
To discuss the clinical data from the MaaT013 program and provide a corporate update, MaaT Pharma will host an investor webcast on Monday, December 13, 2021 at 6:00 pm CET/ 12:00 pm EST.
-
MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013
12/1/2021
MaaT Pharma announced today that it will comment clinical data scheduled to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting and provide a corporate update for shareholders and the broader financial community during a dedicated webcast on Monday, December 13th, 2021 at 12:00 pm EST / 6:00 pm CET).
-
MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
11/9/2021
MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting
-
MaaT Pharma Awarded France Relance Government Grant to Accelerate Development in Immuno-Oncology and Support Manufacturing of Next Generation Microbiome Therapies
7/20/2021
MaaT Pharma, a French clinical-stage biotech company specialized in the development of microbiome-based therapies aiming to restore the microbiome/immune system symbiosis in oncology patients, announced that its MEPA program was awarded a EURO 1.9 million grant from the Plan France Relance.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.